Canada’s regulatory agency approved Samsung Bioepis’ Byooviz as the first ranibizumab biosimilar for the Canadian market for the treatment of ophthalmic conditions.
Health Canada has approved Byooviz, a biosimilar referencing Lucentis (ranibizumab), for the treatment for several ophthalmic conditions. Byooviz represents the first ranibizumab biosimilar to be approved for the Canadian market.
The biosimilar was developed through a commercialization agreement between Samsung Bioepis and Biogen Canada and is indicated for the treatment of:
“We are pleased to have achieved a key milestone with Health Canada’s regulatory approval of our ranibizumab biosimilar….The approval is part of our commitment to providing a treatment option for patients with retinal vascular disorders in Canada,” said Byoungin Jung, vice president and regulatory affairs team leader at Samsung Bioepis, a company statement.
The news comes just over a month after Health Canada approved Ontruzant, a trastuzumab biosimilar referencing Herceptin, also developed by Samsung Bioepis.
Byooviz is the sixth biosimilar developed by Samsung Bioepis to be approved in Canada, following Ontruzant, Brenzys (etanercept) in August 2016, Renflexis (infliximab) in December 2017, Hadlima (adalimumab) in May 2018, and Aybintio (bevacizumab) in November 2021. Brenzys references Enbrel, Renflexis references Rituxan, Hadlima and Simlandi are biosimilars for Humira, and Aybintio references Avastin.
Byooviz was also the first biosimilar for Biogen to receive approval in Canada.
Ranibizumab is an anti-vascular endothelial growth factor therapy for ophthalmic conditions related to the retina, such as AMD, which impacts nearly 2 million people in Canada and accounts for 90% of new cases of legal blindness in the country.
“With an estimated eight million Canadians at risk of losing their sight due to an eye disease and AMD the leading cause of vision loss in those over 50, we are excited to be part of this important milestone in providing new treatment options for those affected by debilitating ophthalmic diseases like retinal vascular disorders…. We believe biosimilars are a key step towards providing more Canadians with access to quality treatment, while offering significant savings to our healthcare system,” said Eric Tse, general manager at Biogen Canada.
The approval was based on nonclinical data and data from randomized, double-masked, parallel group, multicenter phase 3 study that demonstrated comparable efficacy, safety, pharmacokinetics, and immunogenicity of the biosimilar with the reference product in patients with wet AMD.
Previously, Byooviz became the first FDA-approved ophthalmology biosimilar in September 2021 and was approved in August 2021 for marketing authorization in the European Union and the United Kingdom.
In November 2019, Samsung Bioepis and Biogen entered into a commercialization agreement for 2 ophthalmology biosimilars, including Byooviz (SB11) and SB15, an aflibercept biosimilar referencing Eylea. As part of the agreement, Samsung Bioepis oversees the manufacturing and development of the biosimilars and Biogen is in charge of commercialization in the United States, Canada, the European Union, the United Kingdom, Japan, and Australia.
In January 2022, Biogen sold its full ownership stake in Samsung Bioepis for $2.3 billion after it increased it from 15% to 50% in 2012. Under the agreement, Biogen received $1 billion in cash at closing, an $812.5 million payment at the first anniversary of the transaction close, and a $437.5 million at the second anniversary. Biogen is also eligible to receive up to $50 million upon achievement of certain commercial milestones.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.